Skip to main content
NASDAQ:RGEN

Repligen Competitors

$171.96
+2.31 (+1.36 %)
(As of 05/14/2021 12:00 AM ET)
Add
Compare
Today's Range
$168.47
$174.78
50-Day Range
$169.65
$220.95
52-Week Range
$109.38
$228.84
Volume376,197 shs
Average Volume392,594 shs
Market Capitalization$9.44 billion
P/E Ratio209.71
Dividend YieldN/A
Beta0.94

Competitors

Repligen (NASDAQ:RGEN) Vs. AMGN, GILD, VRTX, REGN, BIIB, and ALXN

Should you be buying RGEN stock or one of its competitors? Companies in the sub-industry of "biotechnology" are considered alternatives and competitors to Repligen, including Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), and Alexion Pharmaceuticals (ALXN).

Amgen (NASDAQ:AMGN) and Repligen (NASDAQ:RGEN) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, profitability, institutional ownership, earnings and risk.

Risk and Volatility

Amgen has a beta of 0.76, suggesting that its share price is 24% less volatile than the S&P 500. Comparatively, Repligen has a beta of 0.94, suggesting that its share price is 6% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations for Amgen and Repligen, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Amgen291402.48
Repligen00503.00

Amgen presently has a consensus target price of $255.6190, suggesting a potential upside of 1.69%. Repligen has a consensus target price of $222.75, suggesting a potential upside of 29.54%. Given Repligen's stronger consensus rating and higher possible upside, analysts plainly believe Repligen is more favorable than Amgen.

Earnings & Valuation

This table compares Amgen and Repligen's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amgen$23.36 billion6.18$7.84 billion$14.8216.96
Repligen$270.24 million34.94$21.41 million$1.07160.71

Amgen has higher revenue and earnings than Repligen. Amgen is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

75.2% of Amgen shares are owned by institutional investors. Comparatively, 84.3% of Repligen shares are owned by institutional investors. 0.4% of Amgen shares are owned by company insiders. Comparatively, 1.7% of Repligen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Amgen and Repligen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Amgen29.42%95.55%15.52%
Repligen13.40%6.58%5.00%

Gilead Sciences (NASDAQ:GILD) and Repligen (NASDAQ:RGEN) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, profitability, institutional ownership, earnings and risk.

Profitability

This table compares Gilead Sciences and Repligen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Gilead Sciences5.48%37.77%12.76%
Repligen13.40%6.58%5.00%

Institutional & Insider Ownership

76.4% of Gilead Sciences shares are owned by institutional investors. Comparatively, 84.3% of Repligen shares are owned by institutional investors. 0.1% of Gilead Sciences shares are owned by company insiders. Comparatively, 1.7% of Repligen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Risk and Volatility

Gilead Sciences has a beta of 0.51, suggesting that its share price is 49% less volatile than the S&P 500. Comparatively, Repligen has a beta of 0.94, suggesting that its share price is 6% less volatile than the S&P 500.

Earnings & Valuation

This table compares Gilead Sciences and Repligen's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gilead Sciences$22.45 billion3.83$5.39 billion$6.1411.16
Repligen$270.24 million34.94$21.41 million$1.07160.71

Gilead Sciences has higher revenue and earnings than Repligen. Gilead Sciences is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current recommendations for Gilead Sciences and Repligen, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Gilead Sciences091202.57
Repligen00503.00

Gilead Sciences presently has a consensus target price of $100.5909, suggesting a potential upside of 46.78%. Repligen has a consensus target price of $222.75, suggesting a potential upside of 29.54%. Given Gilead Sciences' higher possible upside, analysts plainly believe Gilead Sciences is more favorable than Repligen.

Vertex Pharmaceuticals (NASDAQ:VRTX) and Repligen (NASDAQ:RGEN) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, dividends, institutional ownership, earnings, risk and valuation.

Profitability

This table compares Vertex Pharmaceuticals and Repligen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Vertex Pharmaceuticals38.51%28.55%20.68%
Repligen13.40%6.58%5.00%

Institutional and Insider Ownership

92.2% of Vertex Pharmaceuticals shares are owned by institutional investors. Comparatively, 84.3% of Repligen shares are owned by institutional investors. 0.7% of Vertex Pharmaceuticals shares are owned by insiders. Comparatively, 1.7% of Repligen shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Volatility and Risk

Vertex Pharmaceuticals has a beta of 0.79, suggesting that its stock price is 21% less volatile than the S&P 500. Comparatively, Repligen has a beta of 0.94, suggesting that its stock price is 6% less volatile than the S&P 500.

Valuation & Earnings

This table compares Vertex Pharmaceuticals and Repligen's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vertex Pharmaceuticals$4.16 billion13.50$1.18 billion$4.2950.60
Repligen$270.24 million34.94$21.41 million$1.07160.71

Vertex Pharmaceuticals has higher revenue and earnings than Repligen. Vertex Pharmaceuticals is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings for Vertex Pharmaceuticals and Repligen, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vertex Pharmaceuticals041612.86
Repligen00503.00

Vertex Pharmaceuticals currently has a consensus target price of $293.4737, indicating a potential upside of 35.19%. Repligen has a consensus target price of $222.75, indicating a potential upside of 29.54%. Given Vertex Pharmaceuticals' higher possible upside, equities analysts clearly believe Vertex Pharmaceuticals is more favorable than Repligen.

Summary

Vertex Pharmaceuticals beats Repligen on 10 of the 15 factors compared between the two stocks.

Regeneron Pharmaceuticals (NASDAQ:REGN) and Repligen (NASDAQ:RGEN) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, dividends, institutional ownership, earnings, risk and valuation.

Profitability

This table compares Regeneron Pharmaceuticals and Repligen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Regeneron Pharmaceuticals38.28%28.97%20.11%
Repligen13.40%6.58%5.00%

Institutional and Insider Ownership

85.0% of Regeneron Pharmaceuticals shares are owned by institutional investors. Comparatively, 84.3% of Repligen shares are owned by institutional investors. 11.8% of Regeneron Pharmaceuticals shares are owned by insiders. Comparatively, 1.7% of Repligen shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Volatility and Risk

Regeneron Pharmaceuticals has a beta of 0.3, suggesting that its stock price is 70% less volatile than the S&P 500. Comparatively, Repligen has a beta of 0.94, suggesting that its stock price is 6% less volatile than the S&P 500.

Valuation & Earnings

This table compares Regeneron Pharmaceuticals and Repligen's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Regeneron Pharmaceuticals$7.86 billion7.04$2.12 billion$21.4724.06
Repligen$270.24 million34.94$21.41 million$1.07160.71

Regeneron Pharmaceuticals has higher revenue and earnings than Repligen. Regeneron Pharmaceuticals is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings for Regeneron Pharmaceuticals and Repligen, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Regeneron Pharmaceuticals051402.74
Repligen00503.00

Regeneron Pharmaceuticals currently has a consensus target price of $656.3810, indicating a potential upside of 27.05%. Repligen has a consensus target price of $222.75, indicating a potential upside of 29.54%. Given Repligen's stronger consensus rating and higher possible upside, analysts clearly believe Repligen is more favorable than Regeneron Pharmaceuticals.

Summary

Regeneron Pharmaceuticals beats Repligen on 9 of the 14 factors compared between the two stocks.

Biogen (NASDAQ:BIIB) and Repligen (NASDAQ:RGEN) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, dividends, institutional ownership, earnings, risk and valuation.

Profitability

This table compares Biogen and Repligen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Biogen35.63%51.00%23.54%
Repligen13.40%6.58%5.00%

Institutional and Insider Ownership

83.5% of Biogen shares are owned by institutional investors. Comparatively, 84.3% of Repligen shares are owned by institutional investors. 0.5% of Biogen shares are owned by insiders. Comparatively, 1.7% of Repligen shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Volatility and Risk

Biogen has a beta of 0.53, suggesting that its stock price is 47% less volatile than the S&P 500. Comparatively, Repligen has a beta of 0.94, suggesting that its stock price is 6% less volatile than the S&P 500.

Valuation & Earnings

This table compares Biogen and Repligen's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biogen$14.38 billion2.93$5.89 billion$33.578.35
Repligen$270.24 million34.94$21.41 million$1.07160.71

Biogen has higher revenue and earnings than Repligen. Biogen is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings for Biogen and Repligen, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Biogen4141202.27
Repligen00503.00

Biogen currently has a consensus target price of $305.5714, indicating a potential upside of 9.05%. Repligen has a consensus target price of $222.75, indicating a potential upside of 29.54%. Given Repligen's stronger consensus rating and higher possible upside, analysts clearly believe Repligen is more favorable than Biogen.

Alexion Pharmaceuticals (NASDAQ:ALXN) and Repligen (NASDAQ:RGEN) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, dividends, institutional ownership, earnings, risk and valuation.

Institutional and Insider Ownership

87.3% of Alexion Pharmaceuticals shares are owned by institutional investors. Comparatively, 84.3% of Repligen shares are owned by institutional investors. 4.0% of Alexion Pharmaceuticals shares are owned by insiders. Comparatively, 1.7% of Repligen shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Alexion Pharmaceuticals and Repligen's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alexion Pharmaceuticals$4.99 billion7.68$2.40 billion$9.7417.81
Repligen$270.24 million34.94$21.41 million$1.07160.71

Alexion Pharmaceuticals has higher revenue and earnings than Repligen. Alexion Pharmaceuticals is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Alexion Pharmaceuticals has a beta of 1.33, suggesting that its stock price is 33% more volatile than the S&P 500. Comparatively, Repligen has a beta of 0.94, suggesting that its stock price is 6% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings for Alexion Pharmaceuticals and Repligen, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Alexion Pharmaceuticals015402.21
Repligen00503.00

Alexion Pharmaceuticals currently has a consensus target price of $159.3158, indicating a potential downside of 8.17%. Repligen has a consensus target price of $222.75, indicating a potential upside of 29.54%. Given Repligen's stronger consensus rating and higher possible upside, analysts clearly believe Repligen is more favorable than Alexion Pharmaceuticals.

Profitability

This table compares Alexion Pharmaceuticals and Repligen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Alexion Pharmaceuticals16.32%23.16%14.76%
Repligen13.40%6.58%5.00%

Summary

Alexion Pharmaceuticals beats Repligen on 9 of the 14 factors compared between the two stocks.


Repligen Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Amgen logo
AMGN
Amgen
2.3$251.38+0.4%$144.43 billion$23.36 billion20.27Insider Selling
Gilead Sciences logo
GILD
Gilead Sciences
2.8$68.53+0.6%$85.95 billion$22.45 billion70.65
Vertex Pharmaceuticals logo
VRTX
Vertex Pharmaceuticals
2.0$217.09+1.3%$56.20 billion$4.16 billion27.41
Regeneron Pharmaceuticals logo
REGN
Regeneron Pharmaceuticals
2.6$516.62+0.1%$55.35 billion$7.86 billion18.88Analyst Report
Biogen logo
BIIB
Biogen
1.5$280.21+0.5%$42.19 billion$14.38 billion9.28
Alexion Pharmaceuticals logo
ALXN
Alexion Pharmaceuticals
1.7$173.49+0.1%$38.34 billion$4.99 billion40.54
Seagen logo
SGEN
Seagen
1.5$147.50+1.9%$26.77 billion$916.71 million58.07Insider Selling
Incyte logo
INCY
Incyte
1.6$82.62+0.7%$18.17 billion$2.16 billion-52.62Analyst Report
Exact Sciences logo
EXAS
Exact Sciences
2.0$96.74+3.2%$16.60 billion$876.29 million-43.77Analyst Report
Analyst Revision
Alnylam Pharmaceuticals logo
ALNY
Alnylam Pharmaceuticals
1.6$135.70+2.0%$15.95 billion$219.75 million-17.33
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
2.1$76.93+1.8%$14.06 billion$1.70 billion17.60Insider Selling
Novavax logo
NVAX
Novavax
1.8$131.69+8.1%$9.76 billion$18.66 million-25.23Earnings Announcement
Analyst Report
Analyst Revision
Neurocrine Biosciences logo
NBIX
Neurocrine Biosciences
2.3$94.60+2.8%$8.94 billion$788.10 million101.72Analyst Report
Unusual Options Activity
United Therapeutics logo
UTHR
United Therapeutics
1.7$197.87+2.1%$8.86 billion$1.45 billion18.72Analyst Report
Exelixis logo
EXEL
Exelixis
1.9$25.56+0.4%$8.01 billion$967.78 million53.25Insider Selling
Halozyme Therapeutics logo
HALO
Halozyme Therapeutics
1.5$43.03+2.9%$6.13 billion$195.99 million268.94Earnings Announcement
Analyst Downgrade
Insider Selling
Analyst Revision
News Coverage
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.6$38.24+2.3%$5.39 billion$1.12 billion79.67Analyst Report
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.7$61.46+1.6%$3.73 billion$806.43 million-8.71Analyst Report
Alkermes logo
ALKS
Alkermes
1.2$22.26+0.1%$3.57 billion$1.17 billion-48.39Insider Selling
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.2$62.00+5.6%$3.32 billion$1.11 billion19.94Analyst Report
Gap Up
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.4$9.49+1.3%$2.52 billion$182.24 million-8.25Earnings Announcement
Analyst Revision
News Coverage
OPKO Health logo
OPK
OPKO Health
1.9$3.70+7.8%$2.48 billion$901.90 million-20.55Insider Buying
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.3$12.84+6.9%$2.28 billion$48.83 million-16.89
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.5$134.70+2.3%$2.23 billionN/A-12.17
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$129.52+4.4%$2.16 billion$120.28 million-130.83
Myriad Genetics logo
MYGN
Myriad Genetics
1.0$27.38+6.3%$2.11 billion$638.60 million-10.53
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.6$11.68+1.7%$1.88 billion$428.41 million16.93
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$10.85+4.1%$1.56 billion$102.43 million-18.08Analyst Revision
ImmunoGen logo
IMGN
ImmunoGen
1.5$6.75+5.2%$1.35 billion$82.27 million-16.46Earnings Announcement
Analyst Revision
Gap Up
Innoviva logo
INVA
Innoviva
1.1$12.87+0.9%$1.30 billion$261.02 million6.57
Curis logo
CRIS
Curis
1.3$13.57+3.7%$1.24 billion$10 million-16.55Earnings Announcement
Analyst Report
Unusual Options Activity
News Coverage
Codexis logo
CDXS
Codexis
1.5$18.29+3.8%$1.18 billion$68.46 million-52.26
MannKind logo
MNKD
MannKind
1.4$4.31+6.5%$1.07 billion$63.04 million-20.52Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Gap Up
Celldex Therapeutics logo
CLDX
Celldex Therapeutics
1.8$27.09+7.7%$1.07 billion$3.57 million-12.15Gap Up
Vanda Pharmaceuticals logo
VNDA
Vanda Pharmaceuticals
1.5$18.65+1.3%$1.04 billion$227.19 million51.81Analyst Report
Dynavax Technologies logo
DVAX
Dynavax Technologies
1.7$7.80+6.0%$893.79 million$35.22 million-5.69Analyst Downgrade
ChemoCentryx logo
CCXI
ChemoCentryx
1.7$10.44+4.5%$728.19 million$36.13 million-15.58Analyst Report
Agenus logo
AGEN
Agenus
1.6$3.23+6.2%$718.48 million$150.05 million-2.96Analyst Upgrade
ZIOPHARM Oncology logo
ZIOP
ZIOPHARM Oncology
1.3$3.17+4.4%$683.21 million$150,000.00-4.53Analyst Report
Bolt Biotherapeutics logo
BOLT
Bolt Biotherapeutics
1.3$18.79+2.4%$682.60 millionN/A0.00High Trading Volume
Gap Down
Rigel Pharmaceuticals logo
RIGL
Rigel Pharmaceuticals
1.6$3.71+2.4%$631.31 million$59.29 million-24.73
Lexicon Pharmaceuticals logo
LXRX
Lexicon Pharmaceuticals
1.6$4.33+3.0%$625.20 million$322.07 million-4.12Analyst Revision
News Coverage
Clovis Oncology logo
CLVS
Clovis Oncology
1.2$5.87+4.3%$613.80 million$143.01 million-1.12Analyst Report
Intercept Pharmaceuticals logo
ICPT
Intercept Pharmaceuticals
2.2$18.15+5.1%$601.89 million$252 million-1.86Analyst Report
Spectrum Pharmaceuticals logo
SPPI
Spectrum Pharmaceuticals
1.5$3.48+12.1%$541.88 million$109.33 million-2.56Earnings Announcement
News Coverage
Verastem logo
VSTM
Verastem
1.5$2.94+4.8%$505.44 million$17.46 million-2.09Earnings Announcement
Analyst Report
News Coverage
Geron logo
GERN
Geron
1.4$1.43+6.3%$455.55 million$460,000.00-4.09Earnings Announcement
Analyst Upgrade
Analyst Revision
Gap Up
Molecular Templates logo
MTEM
Molecular Templates
2.0$7.86+6.1%$440.85 million$22.27 million-3.85Earnings Announcement
News Coverage
Gap Down
Fortress Biotech logo
FBIO
Fortress Biotech
1.6$3.68+1.9%$357.90 million$36.63 million-4.33Upcoming Earnings
XOMA logo
XOMA
XOMA
1.5$29.92+2.1%$337.20 million$18.37 million-26.95
This page was last updated on 5/15/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.